GT200100041A - Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo. - Google Patents

Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo.

Info

Publication number
GT200100041A
GT200100041A GT200100041A GT200100041A GT200100041A GT 200100041 A GT200100041 A GT 200100041A GT 200100041 A GT200100041 A GT 200100041A GT 200100041 A GT200100041 A GT 200100041A GT 200100041 A GT200100041 A GT 200100041A
Authority
GT
Guatemala
Prior art keywords
derivatives
same
legands
disorders
diseases
Prior art date
Application number
GT200100041A
Other languages
English (en)
Inventor
Gary Erik Aspnes
Yuan-Ching Phoebe Chiang
Kimberly Gail Estep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100041A publication Critical patent/GT200100041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS LIGANDOS DE RECEPTOR TIROIDEO, Y MAS ESPECIFICAMENTE SE REFIERE A ACIDOS MALONAMICOS Y DERIVADOS DE LOS MISMOS, QUE SON UTILES EN EL TRATAMIENTO DE OBESIDAD, ESTADO DE SOBREPESO, HIPERLIPIDEMIA, GLAUCOMA, ARRITMIAS CARDIACAS, TRANSTORNOS CUTANEOS, ENFERMEDAD TIROIDEA, HIPOTIROIDISMO, CANCER DE TRIROIDES, TRASTORNOS Y ENFERMEDADES CON LA TIROIDES, TALES COMO DIABETES MELLITUS, ATEROSCLEROSIS, HIPERTENSION, ENFERMEDAD CARDIACA CORONARIA, FALLO CARDIACO CONGESTIVO, HIPERCOLESTEROLEMIA, DEPRESION, Y OSTEOPOROSIS. LA PRESENTE INVECION TRATA TAMBIEN ACERCA DE METODOS, COMPOSICIONES FARMACEUTICAS Y CONJUNTOS PARA TRATAR DICHAS ENFERMEDADES Y TRASTORNOS.
GT200100041A 2000-03-31 2001-03-19 Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo. GT200100041A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
GT200100041A true GT200100041A (es) 2002-03-22

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100041A GT200100041A (es) 2000-03-31 2001-03-19 Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo.

Country Status (38)

Country Link
US (1) US20070173548A1 (es)
EP (1) EP1268404B1 (es)
JP (1) JP3866977B2 (es)
KR (1) KR20020089420A (es)
CN (1) CN1422246A (es)
AP (1) AP2002002634A0 (es)
AR (1) AR033516A1 (es)
AT (1) ATE382602T1 (es)
AU (1) AU2001237665A1 (es)
BG (1) BG107036A (es)
BR (1) BR0109625A (es)
CA (1) CA2403902C (es)
CR (1) CR6742A (es)
CZ (1) CZ20023190A3 (es)
DE (1) DE60132181D1 (es)
DZ (1) DZ3276A1 (es)
EA (1) EA200200921A1 (es)
EE (1) EE200200566A (es)
GT (1) GT200100041A (es)
HK (1) HK1052498A1 (es)
HU (1) HUP0300329A3 (es)
IL (1) IL151376A0 (es)
IS (1) IS6516A (es)
MA (1) MA26886A1 (es)
MX (1) MXPA02009702A (es)
NO (1) NO20024639L (es)
NZ (1) NZ520660A (es)
OA (1) OA12237A (es)
PA (1) PA8513801A1 (es)
PE (1) PE20011186A1 (es)
PL (1) PL358596A1 (es)
SK (1) SK13762002A3 (es)
SV (1) SV2002000357A (es)
TN (1) TNSN01048A1 (es)
TR (1) TR200202249T2 (es)
WO (1) WO2001072692A1 (es)
YU (1) YU74102A (es)
ZA (1) ZA200207444B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
AU2001230929B2 (en) * 2000-02-17 2004-09-23 Bristol-Myers Squibb Co. Aniline-derived ligands for the thyroid receptor
JP2004517851A (ja) * 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
AU2002331145B2 (en) * 2001-08-24 2008-07-10 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2272817A4 (en) * 2008-04-11 2011-12-14 Inst Med Molecular Design Inc INHIBITOR OF PAI-1
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010049946A2 (en) 2008-10-27 2010-05-06 Cadila Healthcare Limited Thyroid receptor ligands
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2695611B1 (en) 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20170112741A1 (en) * 2014-04-09 2017-04-27 Goldcrest Medicine Institute Co., Ltd. Agent for ameliorating skin symptom, hair growth agent or slimming agent
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND
CN112300133A (zh) * 2019-07-31 2021-02-02 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP3878837A1 (en) * 2020-03-11 2021-09-15 OM Pharma SA 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ATE159515T1 (de) * 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
AU3507700A (en) * 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using diphenylether derivatives
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
DZ3276A1 (fr) 2001-10-04
IS6516A (is) 2002-08-21
SV2002000357A (es) 2002-07-16
NZ520660A (en) 2004-03-26
EA200200921A1 (ru) 2003-02-27
PE20011186A1 (es) 2001-11-15
CA2403902A1 (en) 2001-10-04
IL151376A0 (en) 2003-04-10
KR20020089420A (ko) 2002-11-29
US20070173548A1 (en) 2007-07-26
ZA200207444B (en) 2003-09-17
ATE382602T1 (de) 2008-01-15
EP1268404A1 (en) 2003-01-02
TNSN01048A1 (fr) 2005-11-10
JP2003528847A (ja) 2003-09-30
BG107036A (bg) 2003-04-30
HUP0300329A3 (en) 2004-08-30
WO2001072692A1 (en) 2001-10-04
AR033516A1 (es) 2003-12-26
TR200202249T2 (tr) 2003-01-21
PA8513801A1 (es) 2002-02-21
CA2403902C (en) 2007-04-24
EE200200566A (et) 2004-06-15
AU2001237665A1 (en) 2001-10-08
HK1052498A1 (zh) 2003-09-19
AP2002002634A0 (en) 2002-09-30
EP1268404B1 (en) 2008-01-02
YU74102A (sh) 2006-03-03
CN1422246A (zh) 2003-06-04
DE60132181D1 (de) 2008-02-14
CR6742A (es) 2003-11-25
CZ20023190A3 (cs) 2003-10-15
OA12237A (en) 2003-10-23
NO20024639D0 (no) 2002-09-27
BR0109625A (pt) 2003-04-22
NO20024639L (no) 2002-09-27
SK13762002A3 (sk) 2004-01-08
PL358596A1 (en) 2004-08-09
JP3866977B2 (ja) 2007-01-10
MA26886A1 (fr) 2004-12-20
MXPA02009702A (es) 2003-03-27
HUP0300329A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
GT200100041A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo.
GT200000025A (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos.
PA8493701A1 (es) Compuestos para tratar la obesidad
UY27392A1 (es) Derivados del ácido indan acetico y su uso como agentes farmacéuticos, intermediarios, y método de preparación
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
HN1999000124A (es) Derivados de pirazol substituido.
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
UY28144A1 (es) Agentes terapéuticos
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
CU23535A3 (es) Compuestos de purina y usos de los mismos
UY27793A1 (es) Pirazolopiridinas substituidas con carbamato
UY28376A1 (es) Agentes terapéuticos
CL2004000182A1 (es) Compuestos derivados de pirazolotriazina; y composicion farmaceutica util para tratar enfermedades y/o trastornos modulados por antagonistas de receptor de canabinoides, como la obesidad.
ECSP077318A (es) Analogos de biaril piperazinil-piridina sustituidos
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
PA8532201A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
UY28377A1 (es) Agentes terapeuticos
AR053385A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
UY26951A1 (es) Derivados de ácido propiónico